[Effect of FP inhalation and airway inflammation assessed by ECP in asthma].
We studied the effects of fluticasone propionate (FP) inhalation and the airway inflammation in beclomethasone dipropionate (BDP)-resistant bronchial asthma. Twenty-five patients who had used BDP and whose mean PEF was less then 80% were enrolled in this study. After 2 weeks of BDP inhalation. FP inhalation was administered. The total eosinophil count in the peripheral blood (/microliter), their percentage of the total WBC count (% Eos), the count in induced sputum, the serum ECP content and the induced sputum ECP content were measured before and after 6 weeks of FP treatment. There was a significant increase of morning and evening PEF, from 63.1% to 76.1% and from 63.6% to 76.2%, respectively. There was a significant positive correlation between the peripheral blood % Eos and the % increase of PEF (p < 0.01). There was also a significant positive correlation between the induced sputum % Eos and the % increase of PEF (p < 0.05). The induced sputum ECP content was still as high as 180 micrograms/l after FP treatment. The mean % PEF did not reach 80% after FP treatment. This study suggests that airway inflammation persists in some severe asthma patients despite inhalation of FP 800 micrograms.
Haneda
H
H
Department of Respiratory Disease, Sapporo City General Hospital, Sapporo, 060-8604 Japan.
Koizumi
M
M
D000280:Administration, Inhalation; D000368:Aged; D000730:Androstadienes / Q000008:administration & dosage*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D001249:Asthma / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D001507:Beclomethasone; D015415:Biomarkers / Q000032:analysis; D001798:Blood Proteins / Q000032:analysis*; D004351:Drug Resistance; D047091:Eosinophil Granule Proteins; D005260:Female; D000068298:Fluticasone; D006801:Humans; D018836:Inflammation Mediators / Q000032:analysis*; D008297:Male; D008875:Middle Aged; D010366:Peak Expiratory Flow Rate; D012260:Ribonucleases; D013183:Sputum / Q000378:metabolism; D016896:Treatment Outcome
D000730:Androstadienes; D000893:Anti-Inflammatory Agents; D015415:Biomarkers; D001798:Blood Proteins; D047091:Eosinophil Granule Proteins; D018836:Inflammation Mediators; D000068298:Fluticasone; D012260:Ribonucleases; D001507:Beclomethasone